|
Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Exclusive Content from MarketBeat
A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?Author: Jeffrey Neal Johnson. Originally Published: 4/7/2026. 
Key Points
- Abbott's Medical Devices division continues to accelerate, demonstrating the underlying strength within the company's largest business segment.
- Abbott's impressive history of consecutive dividend increases underscores its commitment to consistently rewarding long-term shareholders.
- Strategic acquisitions are positioning Abbott to lead in new high-growth healthcare sectors, securing a powerful pipeline for future expansion.
- Special Report: Have $500? Invest in Elon’s AI Masterplan
In the world of investing, stability is a prized commodity. Few companies embody that stability better than Abbott Laboratories (NYSE: ABT), a diversified healthcare powerhouse and a member of the elite dividend kings. For decades, investors have relied on Abbott for steady growth and dependable income. That long-standing reputation makes its recent performance all the more striking.
Abbott Laboratories’ stock price recently touched a 52-week low, closing just above $100 in the final trading days of March. This sharp selloff has left many questioning whether the foundation of this industry leader is cracking. A closer look at Abbott’s situation suggests a potential disconnect between market sentiment and operational reality. The key question for long-term investors is whether the market’s pessimism is justified or whether this decline represents a compelling value opportunity. Separating the Signal From the NoiseAbbott's recent drop reflects two distinct pressures. The first is an internal headwind from its Nutrition segment. Abbott’s fourth-quarter 2025 earnings report showed a 9.1% organic sales decline in that division, driven mainly by market-share losses in the U.S. pediatric business and pricing dynamics that constrained volume. Management has acknowledged the challenge and outlined a turnaround plan: targeted price and promotion initiatives and a pipeline of at least eight new product launches in 2026, with a forecasted return to growth in the second half of the year. The second factor is external and broader in scope. The market is undergoing a significant capital rotation. During periods of economic optimism, investors often shift money away from defensive sectors like the healthcare sector into higher-beta areas such as artificial intelligence (AI) and the energy sector seeking faster returns. That broad trend has pressured many fundamentally sound healthcare names, including Abbott, for reasons largely unrelated to their individual performance or long-term prospects. Abbott’s Engine Room Is Running StrongWhile Nutrition works through a near-term recovery, Abbott's core remains robust, led by its largest and most profitable division: Medical Devices. That segment is accelerating — posting 10.4% organic growth in the most recent quarter — and helps offset the isolated weakness in Nutrition. The company’s diversified model keeps its overall outlook healthy, with several high-performing areas driving momentum.
Medical Devices: The Medical Devices business is firing on multiple cylinders, fueled by market-leading innovation in critical care areas. Diabetes Care: The FreeStyle Libre franchise of continuous glucose monitors (CGM) remains a major growth engine. The product line, which lets users monitor glucose without routine fingersticks, generated more than $7.5 billion in sales in 2025 and is a primary contributor to Abbott's sustained performance. Cardiovascular Leadership: Abbott is also a dominant player in cardiovascular care. Its Electrophysiology business grew at a double-digit rate, while Structural Heart posted strong organic growth of 8.7%. This strength comes from best-in-class products such as MitraClip and TriClip, which offer minimally invasive valve repair, plus a pipeline of innovations including the recently FDA-approved Volt PFA System for treating atrial fibrillation. Abbott is also positioning itself for future growth through the acquisition of Exact Sciences, a leader in cancer screening and diagnostics best known for its non-invasive colon cancer test, Cologuard. That deal would immediately expand Abbott’s footprint into the rapidly growing, multi-billion-dollar cancer diagnostics market, adding a high-growth vertical expected to contribute meaningfully to revenue over time. Analysts share a generally constructive view. Wall Street maintains a Moderate Buy consensus rating on the stock, and the average 12-month price target is $135.47 — implying potential upside of more than 30% from current levels and signaling belief that the shares may be undervalued. A Bedrock of Reliability for Income InvestorsFor long-term investors focused on income, Abbott’s dividend is one of its most compelling attributes. Abbott is a member of the S&P 500 Dividend Kings, an exclusive group of companies that have increased their dividend for at least 50 consecutive years. That record underscores a longstanding commitment to returning capital through all market cycles. The recent share-price drop has a tangible benefit for new investors: a higher dividend yield. At current prices, Abbott yields about 2.5%, letting investors lock in a richer income stream from a historically reliable payer. The dividend also appears secure: the payout ratio is roughly 68% of earnings, yet the dividend accounts for only about 37% of operating cash flow — indicating ample cash generation to cover payments and support future increases. A Disconnect Between Price and ValueCurrent market sentiment around Abbott seems at odds with its operational picture. A temporary headwind in one division and a broad market rotation have depressed the stock, even as its fundamental growth drivers accelerate. The Medical Devices division continues to deliver strong results, the dividend remains a dependable source of income, and strategic catalysts like the Exact Sciences acquisition could add a meaningful new growth vertical. For investors with a long-term horizon, the present valuation highlights a notable gap between price and underlying value that may warrant serious consideration. |
